ERBB2 and breast cancer: NeoSphere, a Phase II, multicenter study spread across 16 countries for HER2-positive breast cancer patients, was conducted to assess the activity of pertuzumab (PERJETA®) by comparing the therapeutic effects of the conventional combination of trastuzumab (Herceptin®) plus docetaxel with the combination of pertuzumab with either docetaxel or trastuzumab, or both, in a neoadjuvant setting.